Clinical observation of programmed death receptor 1 inhibitor alone in treatment of relapsed/refractory non-Hodgkin lymphoma
10.3760/cma.j.cn115356-20220825-00244
- VernacularTitle:程序性死亡受体1抑制剂单药治疗复发难治非霍奇金淋巴瘤临床观察
- Author:
Jian LYU
1
;
Qin GENG
;
Zhen WANG
Author Information
1. 临沂市肿瘤医院内三科，临沂 276000
- Keywords:
Lymphoma, non-Hodgkin;
Programmed death receptor 1;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2023;32(9):524-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and side effects of programmed death receptor 1 (PD-1) inhibitor in the treatment of relapsed/refractory non-Hodgkin's lymphoma (NHL).Methods:The clinical data of 31 patients with relapsed/refractory NHL treated with PD-1 inhibitor alone in Linyi Cancer Hospital from July 2018 to December 2021 were retrospectively analyzed. The clinical efficacy and adverse reactions were also analyzed.Results:After 3-4 cycles of PD-1 inhibitor treatment alone, 13 cases achieved partial remission, 3 cases achieved stable disease and 15 cases had the progression of disease. The objective remission rate was 41.9% (13/31), and the disease control rate was 51.6% (16/31). The objective remission rate of patients with peripheral T-cell lymphoma was 42.9% (9/21), and the disease control rate was 57.1% (12/21). By the end of follow-up in July 30, 2022, the median progression-free survival time was 8 months (95% CI 1.6-14.4 months) and the median overall survival time was 15 months (95% CI 5.7-24.3 months). The incidence of adverse reactions in the whole group was 67.7% (21/31), of which grade 1-2 occurred in 20 cases, and grade 3-4 occurred in 1 case. Conclusions:PD-1 inhibitor has a certain effect in the treatment of relapsed/refractory NHL; the overall incidence of adverse drug reactions is high, but they are all controllable.
